Stockreport

Royalty Pharma Reports Third Quarter 2025 Results

Royalty Pharma plc - Class A Ordinary Shares  (RPRX) 
US:NASDAQ Investor Relations: ir.reprosrx.com/investor-relations
PDF Portfolio Receipts growth of 11% to $814 million; Royalty Receipts growth of 11%Net cash provided by operating activities of $703 millionRaised full year 2025 guidance: [Read more]